MabVax Therapeutics Holdings, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia

October 11, 2016 11:35 AM

ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia at the Hotel Monaco, along with 60 other companies in the microcap universe. The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of...

Read more

Roka Bioscience, Inc. to present at The MicroCap Conference on October 24-25 in Philadelphia

October 11, 2016 11:33 AM

ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / Roka Bioscience, Inc. (NASDAQ: ROKA) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia at the Hotel Monaco, along with 60 other companies in the microcap universe. The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most...

Read more

Amarillo Biosciences, Inc. Receives Approval of Patent Claims - Treatment of Thrombocytopenia Using Orally Administered Interferon

October 6, 2016 9:30 AM

AMARILLO, TX / ACCESSWIRE / October 6, 2016 / Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that eight claims of its latest patent application, which apply the use of low-dose oral interferon to the reversal of Thrombocytopenia, have been allowed by the U.S. Patent & Trademark Office. The patent is expected to issue before year end, 2016. ABI has full rights to exploit this patent in the U.S., Africa, India, Thailand,...

Read more

Abattis Signs MOU with Global Damon Pharma of South Korea

October 5, 2016 8:37 AM

VANCOUVER, BC / ACCESSWIRE / October 5, 2016 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce that it has entered into a Memorandum of Understanding with Global Damon Pharma ("GDP") of South Korea, to distribute and sell Abattis' proprietary PhytoNOS™ and Sassy™ Tonics in modified formulations. GDP will engage in the research and creation of necessary components for completion...

Read more

American Cryostem Enters Into Agreement To License ACSelerate-Max Cell Culture Medium To PeproTech

October 3, 2016 10:30 AM

EATONTOWN, NJ / ACCESSWIRE / October 3, 2016 / American CryoStem Corporation (OTC: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the licensing of its flagship xeno-free human mesenchymal cell culture medium, ACSelerate-Max™ for production and distribution by PeproTech, Inc., a leading...

Read more

American CryoStem to Participate in World Medical Tourism & Global Healthcare Congress

September 26, 2016 7:00 AM

EATONTOWN, NJ / ACCESSWIRE / September 26, 2016 / American CryoStem Corporation (OTC: CRYO), a leading developer, marketer and licensor of patented adipose tissue based cellular technologies for the regenerative and personalized medicine industries with laboratories in New Jersey, and licensed labs in Tokyo, Hong Kong and Shenzhen, China, today announced that John Arnone, CEO of CRYO will moderate The World Medical Tourism & Global...

Read more

22nd Century Group to Present at The MicroCap Conference on October 24-25 in Philadelphia

September 21, 2016 3:55 PM

ARLINGTON, VA / ACCESSWIRE / September 21, 2016 / 22nd Century Group (NYSE MKT: XXII) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia, along with over 60 other companies in the microcap universe. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management...

Read more

Accurexa Announces Positive FDA Pre-IND Meeting Outcome for its ACX-31 Brain Cancer Program

August 16, 2016 12:20 PM

NEWARK, DE / ACCESSWIRE / August 16, 2016 / Accurexa Inc. (the "Company" or "Accurexa") (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it received a written response from the FDA (U.S. Food and Drug Administration) regarding a pre-IND (Investigational New Drug) meeting request for its ACX-31 program for the local delivery of...

Read more

Abattis Issues Common Shares, Obtains a Credit Facility and a Change in the Board

August 12, 2016 9:28 PM

VANCOUVER, BC / ACCESSWIRE / August 12, 2016 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), announces that today the Company issued 2,621,452 common shares as compensation for services to consultants, directors and employees of the Company for the month ended July 31, 2016, no legend was required on any of the issued shares. The Company is saddened to announce the untimely death of one of its directors, Tim...

Read more

Avolynt Announces Completion of Phase 2b BRID Study of SGLT2 Inhibitor Remogliflozin-Etabonate

August 9, 2016 10:36 AM

Top-line Results to be Available in the Fourth Quarter of 2016 RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / August 9, 2016 / Avolynt, Inc. ("Avolynt"), a privately held biotech company focused on the development of therapeutics for metabolic diseases, announced today that the phase 2b clinical trial of biphasic remogliflozin etabonate ("remogliflozin") has successfully completed last patient last visit. The biphasic remogliflozin etabonate in...

Read more

Watch Remarkable 'Before-After' Patient Recovery Using RenovaCare SkinGun(TM)

July 27, 2016 9:15 AM

NEW YORK, NY and PITTSBURGH, PA / ACCESSWIRE / July 27, 2016 / RenovaCare, Inc., (OTCQB: RCAR), the developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, released a revolutionary 'before and after' video that highlights the transformative treatment of severe burns by spraying a patient's own stem cells on the affected area to rapidly heal wounds. The 90 minute procedure uses a small...

Read more

RBCC Partner n3D Takes Major Step Forward in 3D Bioprinting with Latest Deal

July 25, 2016 7:21 AM

HENDERSON, NV / ACCESSWIRE / July 25, 2016 / Rainbow Coral Corp. (OTCQB: RBCC) partner company n3D has just inked a groundbreaking agreement with a leading preclinical contract research organization (CRO) to screen promising compound cancer via its revolutionary magnetic 3D bioprinting technology. The deal greatly expands n3D's market reach and solidifies the company's position as a potential leader in the bioprinting field. SBH Biosciences...

Read more

Accurexa's ACX-31 Brain Cancer Program Supported by Monkey Toxicity Study Results

July 13, 2016 8:00 AM

NEWARK, DE / ACCESSWIRE / July 13, 2016 / Accurexa Inc. (the "Company") (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that its ACX-31 program for the treatment for brain cancer is supported by the results of a toxicity study conducted in monkeys at Johns Hopkins University. In the toxicity study[1] temozolomide polymer wafers were...

Read more

Accurexa Files Patent Application for its ACX-31 Brain Cancer Program

July 7, 2016 8:00 AM

NEWARK, DE / ACCESSWIRE / July 7, 2016 / Accurexa Inc. (the "Company") (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it filed a new patent application related to its proprietary formulation used in its ACX-31 program. Accurexa is developing its ACX-31 program for the local delivery of temozolomide as adjunctive therapy to BCNU, both...

Read more

FDA Grants Accurexa Pre-IND Meeting for its ACX-31 Program in the Treatment of Brain Cancer

July 5, 2016 8:00 AM

NEWARK, DE / ACCESSWIRE / July 5, 2016 / Accurexa Inc. (the "Company") (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that the U.S. FDA (Food and Drug Administration) has granted Accurexa a pre-IND (Investigational New Drug) meeting requested to discuss the CMC (Chemistry, Manufacturing and Controls), nonclinical and clinical development...

Read more

New Video: Spray-On Stem Cells Rapidly Heal Wounded State Trooper Using RenovaCare SkinGun

June 29, 2016 9:15 AM

NEW YORK, NY and PITTSBURGH, PA / ACCESSWIRE / June 29, 2016 / RenovaCare, Inc., (OTCQB: RCAR), a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, released behind-the-scenes video footage of its medical device for spraying a patient's own stem cells onto burns and wounds for rapid self-healing. The footage includes compelling first-hand testimony and before-and-after images of a...

Read more

Algae Dynamics Corp Finalizes Financing Terms With GHS Investments LLC

June 28, 2016 4:52 PM

TORONTO, ON / ACCESSWIRE / June 28, 2016 / ALGAE DYNAMICS CORP (OTCQB: ADYNF) (the "Company"), a development stage company focused on the commercialization of its proprietary BioSilo® cultivation system for the growth of algae strains for use in the food and health supplement markets, today announced it has finalized the amendment of a previously announced equity financing facility, concurrent with the assignment thereof to a third...

Read more

Accurexa Submits Pre-IND Meeting Request to the U.S. FDA for Its ACX-31 Program

June 22, 2016 9:00 AM

NEWARK, DE / ACCESSWIRE / June 22, 2016 / Accurexa Inc. (the "Company") (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. FDA (Food and Drug Administration) for its ACX-31 program for the local delivery of temozolomide as adjunctive therapy to BCNU,...

Read more

BioNovelus, Inc. Moving to Fully Reporting Status With SEC

June 17, 2016 6:45 AM

SCOTTSDALE, AZ / ACCESSWIRE / June 17, 2016 / BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce that it is taking steps to become a fully reporting company in order in the future to be able to uplist its shares and move to more visible marketplaces. Mr. Jean Ekobo, President/CEO of BioNovelus, Inc., said, "This represents a huge milestone for our Company and its shareholders. It will add a great deal of value for our Company going...

Read more

Phoenix BioTech, BioNovelus, To Tour Central America and Mexico This Summer

June 9, 2016 3:02 PM

PHOENIX, AZ / ACCESSWIRE / June 9, 2016 / BioNovelus, Inc. (PINKSHEETS: ONOV) is pleased to announce the creation of BioNovelus-CostaRica, a legal entity that will register BioNovelus products for each country in Central America. The registration for Costa Rica should be achieved by the end of the third quarter of 2016. BioNovelus President/CEO Jean Ekobo has presented biodegradable fungicide CR-10 to the Costa Rican Coffee Trade Association...

Read more